EMA prepares guidance on stem cell-based medicines
This article was originally published in Scrip
The European Medicines Agency has drawn up some ideas for future guidance on stem cell-containing medicines, with a focus on issues such as the ability of human embryonic stem cells to form teratomas and the need for long-term follow-up of efficacy and safety. The ideas are contained in a "reflection paper" that interested parties are invited to comment on by 30 June.
You may also be interested in...
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.